SANUWAVE Health, Inc. Announces the Eighth “SHOCK THIS” Blog

SUWANEE, GA, April 12, 2018 -- SANUWAVE Health, Inc. (OTCBB: SNWV) announces another installment of their blog, SHOCK THIS on its website www.sanuwave.com.  The eighth blog is titled "Microcirculation Connection with Shock Wave Stimulation - A Personal Perspective from Dr. Maria Siemionow - One of the Great Innovators in Microsurgery and Active Researcher in Shock Wave Clinical Science".  This blog is presented by SANUWAVE's head of Research and Development, Dr. Iulian Cioanta.

This blog is the second of the blog series that SANUWAVE will publish in 2018, with a focus on the opinions of avant-garde researchers in the shock wave field and on new ideas from experts using the shock wave technology.  This installment is an interview with Dr. Maria Siemionow, a transplant surgeon and scientist who led a team of eight surgeons through the world's first near-total face transplant in 2008.  She is regarded as a world leader in nerve regeneration enhancement and in developing minimal immunosuppression regimens following transplantation.  Dr. Siemionow specializes in microsurgery, hand surgery, peripheral nerve surgery, transplantation, and microsurgery research.  As part of her research linked with microsurgery, Dr. Siemionow performed studies on the influence of SANUWAVE’s PACE technology on microcirculation.

The interview with Dr. Siemionow took place during SANUWAVE’s Clinical and Science Symposium from Chateau Elan, Braselton, GA, USA, in December 2017, when Dr. Maria Siemionow and Dr. Iulian Cioanta conversed about the distinguished career of Dr. Siemionow, the impact of her celebrity status, her latest research interests, and future collaboration with SANUWAVE.  For direct access to the blog, please access our company’s website blog section. 

The goal of the blog series is to foster a medium to educate customers, patients, partners, and the public about the various initiatives at SANUWAVE.  The blog will also accept posts and comments (approved by SANUWAVE), which the Company views as valuable to the SANUWAVE community.  This is expected to be a constructive forum for users to access and actively participate in from around the globe.  By having a centralized, web-based location, SHOCK THIS can unite users and feature information that will be useful and entertaining to the SANUWAVE community.  Members of the SANUWAVE community are encouraged to interact and post their thoughts and ideas, which, in turn will positively impact the SANUWAVE community.  SANUWAVE Health, Inc. reserves the right to edit or exclude comments it deems not positively impacting the experience or is not appropriate from legal and regulatory perspectives. 

About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (OTCQB:SNWV) (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is US FDA cleared for the treatment of Diabetic Foot Ulcers.  The device is also CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, South Korea, Australia and New Zealand. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food and industrial markets.

Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.

For additional information about the Company, visit www.sanuwave.com.

Contact:

Millennium Park Capital LLC
Christopher Wynne
312-724-7845
[email protected]

SANUWAVE Health, Inc.
Kevin Richardson II
Chairman of the Board
978-922-2447
[email protected]

SANUWAVE Health, Inc.
Iulian Cioanta, Ph.D.
Vice President of Research and Development
678-578-0106 (Office)
[email protected]